All News
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198
#ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest
Olga Petryna DrPetryna ( View Tweet)
Nice insights into RA-ILD from @jeffsparks:
- assoc (in Medicare): male, smoker, asthma/COPD, b/tsDMARDs, steroids
- mortality risk? Yes, esp resp (sdHR 4.4), cancer
- ACPA/lung inflamm related to RA-ILD? Yes, esp anti-filaggrin (aOR 3.08/log unit)
#ACR20 ABST0489/0490 @RheumNow https://t.co/DGkNNPOcbd
David Liew drdavidliew ( View Tweet)
@Janetbirdope @RheumNow @CRASCRRheum This study is a follow-on to an existing body of evidence re: vitamin K-dependent proteins ("Gla" proteins) in #OA, as well as warfarin VK antagonist effects, and agnostic discovery in a GWAS. The findings hold including in studies unrelated to access to care and a small RCT.
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Be sure to check this session with @CCalabreseDO and Dr. Gordon Lam on the role of IL6 in inflammation, RA, and CRS at 2 pm EST today! #ACR20 @RheumNow https://t.co/c4oX1tNeId
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Sammy Zakaria said we need close communication with cardiologist in myocarditis related to myositis. #ACR20 @RheumNow https://t.co/kTAZKWpw0S
Sole RetamozoSole ( View Tweet)
Did you know? ADA was initially named "Eric" after the fierce soccer star "Eric Daniel Pierre Cantona"! @RheumNow #ACR20 https://t.co/5WvA5Ov3Fu
sheila RHEUMarampa ( View Tweet)
HCQ might decrease risk for NAFLD!
Restrospective study of 5600 pts noted patients on HCQ (despite having more metabolic syndrome, HTN, DM) had 24% less incidence of NAFLD compared to pts not on HCQ
Abstr#0177 #ACR20 @rheumnow
https://t.co/ZoK2aC0ZQR
k dao KDAO2011 ( View Tweet)
Myositis:getting to the Heart. #ACR20 Prof Chung @RheumNow https://t.co/pj9rzmRgyx
Sole RetamozoSole ( View Tweet)
Coding 101 pearls! Under coding is considered fraud per Dr. Vladimir Liarski @vladml @RheumNow #ACR20 https://t.co/idkPJeUzvu
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Taking a break at the #ACR20? Visit https://t.co/KmscOUu8MO and access our online library of the the latest video abstracts, as well as extensive author interviews hosted by our editor. https://t.co/iRxroN2YWN
The Journal of Rheumatology jrheum ( View Tweet)
Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O
Janet Pope Janetbirdope ( View Tweet)
Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data from COASTW & MEASURE2 @RheumNow #ACR2020 @CRASCRRheum https://t.co/GsFjZuZRvI
Janet Pope Janetbirdope ( View Tweet)
@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
Olga Petryna DrPetryna ( View Tweet)
I admit I don’t get it. Warfarin has more cartilage loss than DOACs. Is this real or a reflection of diff access to cheap vs expensive meds?Duration response seen. Need RCT or subanalysis of a fib RCTs. #bestinclass great trainee plenary #934 @RheumNow @CRASCRRheum #ACR20 https://t.co/Eg1ymtDdmI
Janet Pope Janetbirdope ( View Tweet)
Dr. Jonathan Kay with changes in ICD coding from ICD-9 to ICD-10.
And we just got an ICD code for nr-axSpA!
It's M46.80
https://t.co/JAlF4ERoHr
#ACR20 https://t.co/lmElQVtv35
Rheum Cat rheum_cat ( View Tweet)
Billing and coding is important! Trying to learn more at #ACR20 #3S017😖 Common pitfalls noted here @RheumNow New 2021 EM CPT coding comin soon- so things will have to be relearned..:( [PE will go away from billing requirements??]😐 https://t.co/GeBxQ0lb8l
Bella Mehta bella_mehta ( View Tweet)
Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 @RheumNow https://t.co/oDhs1EHSTP
Dr. Rachel Tate uptoTate ( View Tweet)